

# Chiara Corti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2566514/publications.pdf>

Version: 2024-02-01

31  
papers

852  
citations

471509

17  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

670  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.   | 2.8 | 49        |
| 2  | Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.   | 7.7 | 46        |
| 3  | Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.   | 5.2 | 67        |
| 4  | Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817.  | 4.0 | 35        |
| 5  | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.   | 3.5 | 63        |
| 6  | CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.   | 4.1 | 31        |
| 7  | SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207.                                 | 2.8 | 4         |
| 8  | Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395.  | 7.7 | 60        |
| 9  | Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3063-3063.   | 1.6 | 0         |
| 10 | Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. <i>European Journal of Cancer</i> , 2022, 171, 25-42.  | 2.8 | 9         |
| 11 | Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. <i>European Journal of Cancer</i> , 2022, 172, 332-339. | 2.8 | 6         |
| 12 | Commentary: SARS-CoV-2 vaccines and cancer patients. <i>Annals of Oncology</i> , 2021, 32, 569-571.   | 1.2 | 43        |
| 13 | SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327.  | 2.8 | 55        |
| 14 | Antibody-Drug Conjugates for the Treatment of Breast Cancer. <i>Cancers</i> , 2021, 13, 2898.   | 3.7 | 34        |
| 15 | Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.   | 4.4 | 15        |
| 16 | Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. <i>Cancer Treatment Reviews</i> , 2021, 97, 102205.   | 7.7 | 21        |
| 17 | Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. <i>Pharmaceuticals</i> , 2021, 14, 884.   | 3.8 | 17        |
| 18 | First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253.   | 7.7 | 26        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 5829.  | 3.7 | 8         |
| 20 | Novel immune targets for the treatment of triple-negative breast cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 815-834.  | 3.4 | 11        |
| 21 | Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 594-602.   | 2.4 | 6         |
| 22 | PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020, 11, 719.   | 2.4 | 67        |
| 23 | PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.   | 4.1 | 25        |
| 24 | Tubular Adenoma of the Breast. <i>Encyclopedia of Pathology</i> , 2020, , 379-384.  | 0.0 | 0         |
| 25 | Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 270-279.   | 4.3 | 29        |
| 26 | Columnar Cell Lesion and Apocrine Hyperplasia of the Breast: Is There a Common Origin? The Role of Prolactin-induced Protein. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 508-514.     | 1.2 | 11        |
| 27 | Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky056.                                    | 2.9 | 71        |
| 28 | Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. <i>BMC Cancer</i> , 2018, 18, 935. | 2.6 | 32        |
| 29 | Tubular Adenoma of the Breast. <i>Encyclopedia of Pathology</i> , 2018, , 1-6.  | 0.0 | 0         |
| 30 | Lymphovascular invasion and extranodal tumor extension as risk indicators of breast cancer-related lymphedema.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12609-e12609.                                      | 1.6 | 0         |
| 31 | Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. <i>Journal of Visualized Experiments</i> , 2017, , .                                     | 0.3 | 11        |